Depression is a frequent comorbidity of temporal lobe epilepsy (TLE); however, its mechanisms remain poorly understood and effective therapies are lacking. Augmentation of hippocampal interleukin-1β (IL-1β) signaling may be a mechanistic factor of both TLE and clinical depression. We examined whether pharmacological blockade of hippocampal interleukin-1 receptor exerts antidepressant effects in an animal model of comorbidity between TLE and depression, which developed in Wistar rats following pilocarpine status epilepticus (SE). In post-SE animals, depression-like state was characterized by behavioral equivalents of anhedonia and despair; dysregulation of the hypothalamo-pituitary-adrenocortical axis; compromised raphe-hippocampal serotonergic transmission. Two-week long bilateral intrahippocampal infusion of human recombinant Interleukin-1 receptor antagonist (IL-1ra) improved all of the examined depressive impairments, without modifying spontaneous seizure frequency and without affecting normal parameters in naïve rats. These findings implicate hippocampal IL-1β in epilepsy-associated depression and provide a rationale for the introduction of IL-1β blockers in the treatment of depression in TLE.
Introduction
Depression represents one of the most common comorbidities of temporal lobe epilepsy (TLE) and has profound negative impact on the quality of life of TLE patients (Kanner, 2003; Kondziella et al., 2007) . However, the causes and mechanisms of depression in TLE remain poorly understood, partly due to the lack of proper animal models. We previously reported that rats which develop chronic epilepsy following pilocarpine status epilepticus (SE) exhibited set of interictal disorders congruent with depression. Specifically, the following depressive impairments were documented in post-SE animals: behavioral equivalents of anhedonia (i.e. loss of the ability to experience pleasure) and despair; dysregulation of hypothalamopituitary-adrenocortical (HPA) axis; and compromised raphe-hippocampal serotonergic transmission (Mazarati et al., 2008 (Mazarati et al., , 2009a . As the pilocarpine model reproduces both epileptic and depressive states, it may serve as a model of comorbidity between TLE and depression and as such, can be used both for studying mechanisms of this condition and as a screening platform for therapeutic interventions. Since depression is a multisymptomatic and a multifactorial disorder, further studies are necessary to advance the validation of this model; however, the impairments established up to date allow initial experimental therapy studies.
One factor which may contribute to depression in TLE is hippocampal tissue inflammation and, particularly, enhanced interleukin-1β (IL-1β) signaling. Indeed, activation of hippocampal IL-1β and its receptor (IL-1R) has been an established hallmark of TLE both in clinical and experimental settings and has been implicated in mechanisms of epileptogenesis (Bartfai et al., 2007; Ravizza et al., 2008; Vezzani et al., 2002 Vezzani et al., , 2008 Vezzani and Granata, 2005) . At the same time, IL-1β and other inflammatory cytokines may lead to depression conceivably via inducing perturbation in the HPA axis, as suggested by clinical observations, and confirmed by experimental studies (Capuron and Dantzer, 2003; Dunn et al., 2005; Leonard, 2006) . Particularly, the dysregulation of the HPA axis (which represents a neuroendocrine hallmark of depression; Kondziella et al., 2007; Swaab et al., 2005) can be induced by the direct activation of hippocampal IL-1β signaling (Melik Parsadaniantz et al., 1999) .
Such connections between epilepsy and IL-1β on the one hand and IL-1β and depression on the other hand prompted us to examine whether protracted pharmacological blockade of hippocampal IL-1R exerts antidepressant effect in the post-SE model of comorbidity between epilepsy and depression.
Methods

Subjects
The experiments were performed in male Wistar rats (Charles River, Wilmington, MA), 50 days old at the beginning of the study, in accordance with the policies of the National Institutes of Health. 
